![Jing Rong Cui](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jing Rong Cui
Oprichter bij Blossomhill Therapeutics, Inc.
Actieve functies van Jing Rong Cui
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Blossomhill Therapeutics, Inc.
![]() Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation. | Directeur/Bestuurslid | - | - |
Algemeen Directeur | - | - | |
Oprichter | - | - | |
President | - | - |
Loopbaan van Jing Rong Cui
Eerdere bekende functies van Jing Rong Cui
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
TURG POIN | Directeur/Bestuurslid | 01-10-2013 | 01-09-2018 |
Voorzitter | 01-09-2018 | - | |
Hoofd Techniek/Wetenschap/O&O | 01-10-2013 | 31-01-2020 | |
Oprichter | 01-10-2013 | 15-06-2020 | |
President | 01-04-2018 | 01-01-2019 |
Opleiding van Jing Rong Cui
The Ohio State University | Doctorate Degree |
University of Science & Technology of China | Graduate Degree |
Statistieken
Internationaal
Verenigde Staten | 4 |
China | 2 |
Operationeel
Director/Board Member | 2 |
Founder | 2 |
President | 2 |
Sectoraal
Health Technology | 3 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Turning Point Therapeutics, Inc.
![]() Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Blossomhill Therapeutics, Inc.
![]() Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation. | Health Technology |
- Beurs
- Insiders
- Jing Rong Cui
- Ervaring